Labiana Health SA
MAD:LAB
Labiana Health SA
Other Items
Labiana Health SA
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Labiana Health SA
MAD:LAB
|
Other Items
-€938.3k
|
CAGR 3-Years
54%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
Almirall SA
MAD:ALM
|
Other Items
€10.6m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-6%
|
|
|
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
|
Other Items
-€21.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-8%
|
|
|
F
|
Faes Farma SA
MAD:FAE
|
Other Items
-€57.2m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
|
Laboratorio Reig Jofre SA
MAD:RJF
|
Other Items
-€4.6m
|
CAGR 3-Years
33%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
Labiana Health SA
Glance View
Labiana Health SA manufactures sterile and lyophilized dosage forms. The company is headquartered in Pozuelo De Alarcon, Madrid and currently employs 477 full-time employees. The company went IPO on 2022-06-24. The Firm, through its subsidiaries, is engaged in the development, manufacturing and marketing of animal and human medicines. The Company’s main activities are: Drug research and development (R&D), which includes galenic and analytical development; Drug manufacturing, which focuses on formulation development, formulation optimization, bacterial vaccine manufacturing, among others; Regulatory services, which carries out registration procedures for pharmaceutical products in world markets. The Company, through its subsidiaries, is present in Ecuador, Mexico, Serbia and Turkey.
See Also
What is Labiana Health SA's Other Items?
Other Items
-938.3k
EUR
Based on the financial report for Dec 31, 2024, Labiana Health SA's Other Items amounts to -938.3k EUR.
What is Labiana Health SA's Other Items growth rate?
Other Items CAGR 5Y
37%
The average annual Other Items growth rates for Labiana Health SA have been 54% over the past three years , 37% over the past five years .
